title: Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
abstract: The optimal treatment for locally advanced laryngeal cancer remains controversial. The purpose of this trial was to determine if the response to induction chemotherapy could select patients for organ preservation protocols, and improve larynx-preservation rates without compromising overall survival (OS).
  
  
  
  The cohort comprised 12 patients with T3 disease and 14 with T4. Induction chemotherapy consisted of docetaxel, cisplatin, and 5-fluorouracil (TPF). Response to the first cycle was determined by examination and positron emission tomography (PET)-CT. Responders (>50% tumor reduction) underwent chemoradiation, whereas nonresponders underwent laryngectomy.
  
  
  
  Eighty-three percent of the patients had a response and 17% had stable or progressive disease. At 2 years, the median OS was 80%, the larynx-preservation rate was 83%, and the disease-specific survival rate was 86%. Response to a single TPF cycle was associated with 2-year OS (92% vs 50%; p = .02). The T classification was not predictive of survival.
  
  
  
  Response to a single TPF-based cycle may identify patients with advanced laryngeal cancer who are amenable to organ preservation treatment. © 2016 Wiley Periodicals, Inc. Head Neck 39: 227-233, 2017.
authors.affiliation: Head and Neck Tumor Unit, Davidoff Cancer Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: Aron
authors.initials: A
authors.lastname: Popovtzer
authors.affiliation: Department of Nuclear Medicine, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: Hanna
authors.initials: H
authors.lastname: Burnstein
authors.affiliation: Head and Neck Tumor Unit, Davidoff Cancer Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: Salomon
authors.initials: S
authors.lastname: Stemmer
authors.affiliation: Head and Neck Tumor Unit, Davidoff Cancer Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: Dror
authors.initials: D
authors.lastname: Limon
authors.affiliation: Department of Otolaryngology - Head and Neck, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Ohad
authors.initials: O
authors.lastname: Hili
authors.affiliation: Department of Otolaryngology - Head and Neck, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Gideon
authors.initials: G
authors.lastname: Bachar
authors.affiliation: Department of Nuclear Medicine, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: Vladamir
authors.initials: V
authors.lastname: Sopov
authors.affiliation: Department of Otolaryngology - Head and Neck, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Raphael
authors.initials: R
authors.lastname: Feinmesser
authors.affiliation: Department of Nuclear Medicine, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: David
authors.initials: D
authors.lastname: Groshar
authors.affiliation: Department of Otolaryngology - Head and Neck, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Jacob
authors.initials: J
authors.lastname: Shvero
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D007828:Laryngoscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D059351:Organ Sparing Treatments / Q000379:methods*; D011379:Prognosis; D012074:Remission Induction; D018570:Risk Assessment; D000077195:Squamous Cell Carcinoma of Head and Neck; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D002945:Cisplatin; D005472:Fluorouracil
keywords: T4 larynx; concomitant chemotherapy; induction chemotherapy; organ preservation; response